Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

(2015) P. Mitchell et al.   ANNALS OF ONCOLOGY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Mucins in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications

(2015) Imayavaramban Lakshmanan et al.   Journal of Thoracic Oncology

ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options

(2014) Conor E. Steuer et al.   CANCER

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer

(2014) S. Koido et al.   CLINICAL CANCER RESEARCH

Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer

(2014) Seigo Miyoshi et al.   International Journal of Clinical Oncology

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

(2013) Jacques Cadranel et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy

(2012) E. Giroux Leprieur et al.   LUNG CANCER

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

(2011) Marijo Bilusic et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mucins in human neoplasms: Clinical pathology, gene expression and diagnostic application

(2011) Suguru Yonezawa et al.   PATHOLOGY INTERNATIONAL

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03

(2009) Satoshi Teramukai et al.   EUROPEAN JOURNAL OF CANCER

Dendritic cell vaccination and immune monitoring

(2008) E. H. J. G. Aarntzen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

MHC-Unrestricted Lysis of MUC1-Expressing Cells by Human Peripheral Blood Mononuclear Cells

(2008) Stephen E. Wright et al.   IMMUNOLOGICAL INVESTIGATIONS